Actively Recruiting

Phase 4
Age: 6Years - 20Years
All Genders
NCT06465641

Methylphenidate in KBG Syndrome: N-of-1 Series

Led by Radboud University Medical Center · Updated on 2024-12-27

15

Participants Needed

1

Research Sites

150 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial\] is to learn about the effect of methylphenidate in children and adolescents with KBG syndrome. The main question it aims to answer is: • What is the effectiveness of methylphenidate on attention deficit and ADHD-related symptoms in children and adolescents with KBG syndrome? Participants will receive multiple blocks of treatment with methylphenidate and placebo and fill out various questionnaires.

CONDITIONS

Official Title

Methylphenidate in KBG Syndrome: N-of-1 Series

Who Can Participate

Age: 6Years - 20Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 6-20 years
  • Molecularly confirmed diagnosis of KBG syndrome (pathogenic ANKRD11 variant or chromosome 16q24 deletion including ANKRD11)
  • Attention deficit or ADHD-related symptoms or formal ADHD diagnosis with significant impact on daily life
  • Presence of a caregiver or supervisor for proxy reports
Not Eligible

You will not qualify if you...

  • Family history of acute cardiac death requiring further cardiac investigation
  • History of cardiovascular disease such as severe hypertension, heart failure, arterial occlusive disease, life-threatening arrhythmias, angina pectoris, significant congenital heart defect, cardiomyopathy, myocardial infarction, or channelopathy
  • Current or past hyperthyroidism, glaucoma, or pheochromocytoma
  • Use of psychotropic or stimulant drugs interacting with methylphenidate
  • History of schizophrenic or psychotic disorder
  • Unstable epilepsy not controlled with medication
  • History of frequent drug or alcohol abuse
  • Excessive alcohol or drug use or intoxication during the study
  • Pregnant or lactating women
  • Inability to understand or speak Dutch

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands, 6500 HB

Actively Recruiting

Loading map...

Research Team

C

Charlotte Ockeloen, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here